1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
enVVeno Medical Corporation

enVVeno Medical Corporation

NVNOW
enVVeno Medical CorporationUS flagNASDAQ Capital Market
0.01
USD
+0.00
- -
73.65MMarket Cap
enVVeno Medical Corporation
NVNOW
(NASDAQ Capital Market)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-592.84
-1,445.89
-4,039.17
-22,681.85
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
Depreciation Expense
-2
-3
-8
-13
-8
-9
-17
-25
-24
-22
-22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-431.03
-1,845.83
-6,991.46
-24,406.74
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3
-2
-8
1
- -
6
53
38
46
42
29
Working Capital
- -
- -
- -
- -
1
- -
2
1
1
1
1
LT Debt
-4
-4
-6
2
1
7
54
39
46
42
29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
39
36
31
Cash, Cash Equivalents & STI
39
35
31
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
2
Payables & Accruals
1
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
253.04%
-8.75%
Free Cash Flow
- -
23.83%
-10.67%
Net Income, GAAP
- -
27.62%
-7.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Theradiag S.A. (ALTER.PA)
Echo Therapeutics, Inc. (ECTE)
TriSalus Life Sciences, Inc. (TLSI)
Creo Medical Limited (CREO.L)
TruScreen Group Limited (TRU.NZ)
Nexeon MedSystems Inc. (NXNN)
Business
enVVeno Medical Corporation is a medical device firm dedicated to advancing innovative bioprosthetic, tissue-engineered solutions to elevate the treatment standard for venous diseases. The company’s primary focus includes its pioneering VenoValve, a surgical implant developed to address severe deep venous chronic venous insufficiency by acting as a one-way valve to help restore appropriate blood flow within the leg. Although the VenoValve recently received an unfavorable supervisory appeal decision from the U.S. Food and Drug Administration regarding its Premarket Approval application, enVVeno is now strategically shifting its resources toward its next-generation, non-surgical transcatheter-based replacement venous valve, enVVe. The enVVe program is progressing, with an Investigational Device Exemption application anticipated by mid-2025 for a pivotal clinical trial. Incorporated in 1999 and previously known as Hancock Jaffe Laboratories, Inc. until its name change in October 2021, enVVeno Medical Corporation maintains its operations in Irvine, California.